Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Merck & Co (NY: MRK )

101.16 +1.98 (+2.00%)
Official Closing Price Updated: 7:00 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
Why Is Merck Stock Trading Higher On Monday?
Merck's ZENITH trial shows Winrevair significantly lowers morbidity or mortality risk in PAH patients, building on earlier Phase 3 STELLAR results. 
Via Benzinga
Why NYSE:MRK provides a good dividend, while having solid fundamentals.
Why the dividend investor may take a look at MERCK & CO. INC. (NYSE:MRK). 
Via Chartmill
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns
Pyxis Oncology announces mixed Phase 1 PYX-201 data, collaboration with Merck, and analyst downgrade citing limited efficacy beyond head-and-neck cancer. 
Via Benzinga
2 Beaten-Down Healthcare Stocks to Buy Hand Over Fist
Via The Motley Fool
NYSE:MRK appears to be flying under the radar despite its strong fundamentals.
In a market where value is scarce, MERCK & CO. INC. (NYSE:MRK) offers a refreshing opportunity with its solid fundamentals. 
Via Chartmill
Merck's Multi-Billion Dollar Drug Keytruda's Investigational Under The Skin Injection At Par With Intravenous Formulation In Untreated Lung Cancer Patients
Merck's Phase 3 trial shows subcutaneous pembrolizumab is as effective as IV Keytruda for first-line NSCLC treatment, meeting key pharmacokinetic goals. 
Via Benzinga
Why NYSE:MRK is a Top Pick for Dividend Investors.
Why MERCK & CO. INC. (NYSE:MRK) qualifies as a good dividend investing stock. 
Via Chartmill
Not-So-Big Pharma
Thanks to the change in the Health and Human Services Department, 'big pharma' stocks are one of the very few sectors in equity-land that are seemingly unhappy about the forthcoming administration. 
Via Talk Markets
Powell Speaks The Truth - Market Does Not Like It, Consternation About Kennedy, Gaetz, And Hegseth
To gain an edge, this is what you need to know today. 
Via Benzinga
European And US Vaccine Stocks Are Under Pressure - Here's WHy
Vaccine stocks react to Robert F. Kennedy Jr.'s HHS nomination. FDA and NIH express concerns over his anti-vaccine views amid market shifts. 
Via Benzinga
Exposures Product Safety
Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial
Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, and chemotherapy. 
Via Benzinga
Merck Spends Up To $3.3 Billion In An Insurance Policy Against Summit Therapeutics
Merck is spending up to $3.3 billion in a licensing deal for an anti-PD-1/VEGF drug from China. 
Via Investor's Business Daily
Why Are These 3 Vanguard ETFs Underperforming the S&P 500 Since Election Day?
Stocks in these "safe" sectors are selling off as investors gravitate toward growth. 
Via The Motley Fool
Topics ETFs Stocks
Exposures US Equities
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Biotech Stocks Are Rallying: What Is Your Playbook?
If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers. 
Via Talk Markets
3 Stocks Poised for a Breakout
All 3 stocks are high on my watchlist. 
Via The Motley Fool
MarketBeat Week in Review – 11/4 - 11/8
Markets rallied strongly this week on clarity about the election and an expected rate cut, but next week's inflation readings will determine if momentum lasts 
Via MarketBeat
Topics Economy Government
Exposures Interest Rates Political
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and... 
Via Benzinga
2 Hot Biopharma Stocks to Buy and Hold for 5 Years
If you're patient, these businesses have a lot of promising projects in the works. 
Via The Motley Fool
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows.
These stocks have seen better days but investors shouldn't count them out in the long run. 
Via The Motley Fool
Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Via Benzinga
Jim Cramer: This Financial Stock Is A Buy, Likes Broadcom
Broadcom expanded its multi-year partnership with Telia Company to advance telecom and cloud infrastructure using VMware's product portfolio. 
Via Benzinga
2 Magnificent Stocks to Buy That Are Near 52-Week Lows
These stocks near 52-week lows could be ready to rebound. 
Via The Motley Fool
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
After strong earnings reports, Merck may be a better choice than Bristol-Meyers in the short term - but both may present a challenge for buy-and-hold investors. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 price target amid strong trial results. 
Via Benzinga
Summit Therapeutics: Is Their Lung Cancer Drug a Game Changer?
Summit Therapeutics Inc. aims to advance Ivonescimab, a potential breakthrough for NSCLC. The FDA's Fast Track designation boosts its U.S. clinical pathway. 
Via MarketBeat
Exposures Product Safety
Is Pfizer Stock a Bargain for Long-Term Investors?
Wall Street's bearish take on this proven innovator may not be warranted. 
Via The Motley Fool
Is It Time to Buy October's Worst-Performing Dow Jones Stocks?
The Dow finished October down slightly. Should you buy any of these blue chips? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Magnificent Stocks Under $100 to Buy in November
The price could be right for these stocks. 
Via The Motley Fool
2 Dividend Stocks to Buy for a Lifetime of Passive Income
These are the kinds of stocks that can allow investors to sleep easy at night. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.